SABSW underwent a massive financial transformation with stockholders' equity surging 483% to $151.5M and flipping from a $34.1M net loss to $13.3M profit, while simultaneously refining their business focus from general immunology disorders to specifically multi-specific, high-potency treatments.
This dramatic improvement suggests either a major equity raise, asset revaluation, or business combination that fundamentally strengthened the company's balance sheet. The shift to profitability while maintaining increased R&D spending (higher capex, higher operating losses) indicates potential milestone payments, licensing deals, or other non-operating income that could validate their platform technology.
SABSW experienced extraordinary balance sheet growth with total assets nearly quadrupling to $172.8M and current assets increasing 325% to $101.1M, primarily funded by what appears to be significant equity financing given the 483% surge in stockholders' equity. The company achieved a remarkable turnaround from -$34.1M to +$13.3M net income despite operating losses widening to -$49.0M and operating cash flow declining to -$44.8M, suggesting substantial non-operating gains. This financial profile indicates a well-capitalized clinical-stage company that recently secured major funding while continuing to invest heavily in operations and R&D.
Equity base grew 483.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Current assets grew 324.7% — improving short-term liquidity or inventory/receivables build.
Asset base grew 291% — expansion through organic growth, acquisitions, or capital deployment.
Capital expenditure jumped 176.7% — major investment cycle underway; assess returns on deployment.
Net income grew 138.9% — bottom-line growth signals improving overall business health.
Current liabilities surged 33.9% — significant near-term obligations; verify ability to meet short-term debt.
Operating cash flow fell 30.6% — earnings quality concerns; investigate working capital changes and non-cash items.
Cash grew 18% — improving liquidity position supports investment and shareholder returns.
Liabilities increased 17% — monitor debt-to-equity ratio and interest coverage.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →